

GLAXOSMITHKLINE PLC

Form 6-K

January 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 16 January 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- |                                       |                           |
|---------------------------------------|---------------------------|
| a) Name                               | Dr M M Slaoui             |
| b) Position/status                    | Chairman, Global Vaccines |
| c) Initial notification/<br>amendment | Initial notification      |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |  |   |
|--|---|
| a) Description of the financial instrument | American Depositary Shares ('ADSs')<br>ISIN: US37733W1053 |
|--|---|

- |                              |   |
|------------------------------|---|
| b) Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan. |
|------------------------------|---|

- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | \$39.01  | 1539.029  |
|                           | \$39.01  | 1707.721  |
|                           | \$39.01  | 1955.582  |

- |                           |           |
|---------------------------|-----------|
| d) Aggregated information | 5,202.332 |
| Aggregated volume Price   | \$39.01   |

- |                            |            |
|----------------------------|------------|
| e) Date of the transaction | 2017-01-12 |
|----------------------------|------------|

- |                             |     |
|-----------------------------|-----|
| f) Place of the transaction | n/a |
|-----------------------------|-----|

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')

- |                                       |                                 |
|---------------------------------------|---------------------------------|
| a) Name                               | Mr N Hiron                      |
| b) Position/status                    | SVP, Global Ethics & Compliance |
| c) Initial notification/<br>amendment | Initial notification            |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |  |   |           |
|--|---|-----------|
| a) Description of the financial instrument           | American Depositary Shares ('ADSs')<br>ISIN: US37733W1053   |           |
| b) Nature of the transaction                         | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan. |           |
| c) Price(s) and volume(s)                            | Price(s)  | Volume(s) |
|  | \$39.01   | 92.739    |
| d) Aggregated information<br>Aggregated volume Price | n/a (single transaction)  |           |
| e) Date of the transaction                           | 2017-01-12  |           |
| f) Place of the transaction                          | n/a   |           |

1. Details of PDMR/person closely associated with them ('PCA')

- |                    |                              |
|--------------------|------------------------------|
| a) Name            | Mr B McNamara                |
| b) Position/status | CEO, GSK Consumer Healthcare |

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan.

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
|                           | \$39.01  | 230.627   |
| c) Price(s) and volume(s) | \$39.01  | 46.151    |
|                           | \$39.01  | 388.469   |
|                           | \$39.01  | 77.719    |
|                           | \$39.01  | 599.548   |

d) Aggregated information 1,342.514  
Aggregated volume Price \$39.01

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D E Troy

b) Position/status SVP & General Counsel

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan.

|                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | \$39.01  | 953.928   |
|                           | \$39.01  | 1058.486  |
|                           | \$39.01  | 1228.038  |

d) Aggregated information  
Aggregated volume Price 3,240.452  
\$39.01

e) Date of the transaction 2017-01-12

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr K Slaoui

b) Position/status PCA of Dr M M Slaoui  
(Chairman, Global Vaccines)

- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depository Shares ('ADSs')  
ISIN: US37733W1053
- b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan.
- |                             | Price(s)                | Volume(s) |
|-----------------------------|-------------------------|-----------|
| c) Price(s) and volume(s)   | \$39.01                 | 27.931    |
|                             | \$39.01                 | 26.461    |
|                             | \$39.01                 | 25.012    |
| d) Aggregated information   | 79.404                  |           |
|                             | Aggregated volume Price | \$39.01   |
| e) Date of the transaction  | 2017-01-12              |           |
| f) Place of the transaction | n/a                     |           |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 16, 2017

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc